Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
C A
R
GI SE
No Effect on H. Influenza
Bad Compliance
Cephalosporin
Erythromycin
H. Influenza Resistance
S. Pneumonia resistance
No Coverage on A typical Infections
Macrolides
Pharmacology
Distribution
Extensive tissue and cellular distribution clarithromycin
and azithromycin with extensive penetration
Minimal CSF penetration
Elimination
Clarithromycin is the only macrolide partially eliminated
by the kidney (18% of parent and all metabolites); requires
dose adjustment when CrCl < 30 ml/min
Hepatically eliminated: ALL
NONE of the macrolides are removed during hemodialysis!
Variable elimination half-lives (1.4 hours for erythro; 3 to 7
hours for clarithro; 68 hours for azithro)
Dec 17, 2015
Causative Pathogen
Class
Pharyngitis/Tonsillitis
Streptococcus pyogenes
G+
H. influenzae,
G Moraxella catarrhalis
G Streptococcus pneumoniae G +
H. Influenzae
H. parainfluenzae
Moraxella catarrhalis
Streptococcus pneumoniae
Haemophilus influenzae
G Moraxella catarrhalis
G Streptococcus pneumoniae G+
GG GG+
Indication
Causative Pathogen
Class
Community-Acquired Pneumonia
H. Influenzae,
Mycoplasma pneumoniae,
Streptococcus pneumoniae
Chlamydia pneumoniae (TWAR)
G
Others
G+
Others
Staphylococcus aureus
Streptococcus pyogenes
G+
G+
Disseminated mycobacterial
infections
Mycobacterium avium,
Mycobacterium intracellulare
Others
Others
Others
Morning
Evening
Duration of
treatment/day
Acute bronchitis
250 mg
250 mg
AECB / COPD
500mg
500mg
7-14
CAP
250-500mg
250-500mg
7-14
Acute maxillary
sinusitis
500mg
500mg
14
Tonsillitis /
pharingitis
250mg
250mg
10
Infection
KLARICARE XL Tabs
Dosage (q24h)
Duration (Days)
H.influenzae
2 x 500mg
14
M.catarrhalis
2 x 500mg
14
S.pneumoniae
2 x 500mg
14
24/1/2012
Infection
KLARICARE XL Tabs
Dosage (q24h)
Duration (Days)
H.influenzae
2 x 500 mg
H.parainfluenzae
2 x 500 mg
M.catarrhalis
2 x 500 mg
S.pneumoniae
2 x 500 mg
Acute exacerbation of
chronic bronchitis due to:
24/1/2012
10
Clarithromycin ER tablets
Trade name : KlaricareXL500 .
11
Drug Interaction
Drug
Interaction
Theophylline
Verapamil
Carbamazepine
Terfenadine
12
clarithromycin IR
90%
90%
93%
Abdominal pain
1.7%
0.2%
Respiratory infection
Nonantibacterial
Anti-inflammatory
Chemotaxis
Cytokine production
ROS production
Adhesion molecule expression
Antisecretory
Mucus secretion
Chronic airway inflammation
Chronic airway hypersecretion
Disease-modifying benefits
RSV Facts
Most common cause of
bronchiolitis & pneumonia in
children under 1
25-40% of children develop
bronchiolitis or pneumonia
during first RSV infection
31/1,000 under 1 yr. are
hospitalized with RSV
2% will die
16
Pathogenesis
Bronchiolitis
Virus induced necrosis of bronchioloar epithelium
Hypersecretion of mucous
Round cell infiltration and edema of the surrounding
submucosa
17
STUDY OBJECTIVES:
to investigate the efficacy of clarithromycin in
the treatment of RSV bronchiolitis.
- 3weeks treatment
RESULTS
Primary end points
19
RESULTS
Primary end points
20
RESULTS
Primary end points
21
RESULTS
Primary end points
22
RESULTS
23
CONCLUSION:
In RSV bronchiolitis, treatment with clarithromycin had a
statistically significant effect on LOS, use of 2-agonist
treatment and plasma IL-4, IL-8 and eotaxin levels.
24
Bronchiolitis
COPD
Asthma
Chronic Rhinosinusitis
Chronic Rhinosinusitis
Chronic rhinosinusitis is a common disorder of chronic
inflammation of the upper respiratory tract.
It is associated with significant symptoms and impairment
of the quality of life of sufferers.
Chronic inflammation of the mucosa of the nasal cavity
and paranasal sinusitis is one of the hallmarks of chronic
rhinosinusitis.
The inflammation is demonstrated by an increased
number of chronic inflammatory cells, elevated levels of
pro-inflammatory cytokines, increased expression of
adhesion molecules and metaplastic changes in the
epithelium.
12/17/15
12/17/15
Rhinosinusitis Definition
American Academy of
Otolaryngology (AAO) definitionan inflammation of the nose and sinuses
Rhinosinusitis
Include nasal airway
inflammation (Rhinitis)
12/17/15
12/17/15
Introduction
Administration of macrolide is effective in treatment of
chronic rhinosinusitis
Corticosteroids are present the drug of choice in the treatment
of chronic airway inflammation
Study Purpose: To investigate the ability of Clarithromycin in
reducing cytokine production by chronic rhinosinusitis
mucosa.
12/17/15
Results
The concentration dependent reduction in IL-5 , IL-8 and GMCSF production by specimens cultured in the presence of
clarithromycin was significant.
Prednisolone also showed significant concentration effect on
reduction of IL-5, IL-8 and GM-CSF
12/17/15
12/17/15
12/17/15
12/17/15
Discussion
Clarithromycin has previously been shown to inhibit cytokine
production in various cell types.
IL-5 and GM-CSF was shown to be significantly reduced in
nasal polyp tissue after treatment with corticosteroids
12/17/15
Conclusion
The present study has provided further evidence that
Clarithromycin is capable of inhibiting cytokine
production.
Efficacy comparable to the well known established antiinflammatory agent prednisolone.
12/17/15
12/17/15
38
39
24/1/2012
40
(1*)
Guay DR, Gustavson LE, Devcich KJ, Zhang J,Cao G, Olson CA.Clin
Ther2001;23:566-577 PubMed .
24/1/2012
41
42
Thank you